SS-31 peptide claims on TikTok: what the studies actually say

What did @msnicolelynnshops actually say?

The creator argued that SS-31 looked promising in early small-scale studies between 2018 and 2022, but that larger human trials failed to deliver. In her words, clinicians hoped people would "walk longer and feel less fatigued" and "that is not what they found." She concluded that SS-31 is likely only meaningful for people with specific chronic conditions like Barth syndrome (BTHS), and that healthy individuals should not expect much benefit. She closed with a reasonable call to action: talk to your doctor, get tested, and read the actual clinical trials before making decisions. That is a fair summary of where the research stands, with a few things worth untangling.

Does the science back this up?

Mostly yes, and more specifically than she lets on. The claim that larger trials disappointed is well-supported. The TAZPOWER trial, the most significant Phase II randomized controlled trial of elamipretide (the pharmaceutical name for SS-31), enrolled patients with primary mitochondrial myopathy (PMM). Results published by Karaa et al. (2020, JAMA Neurology) showed no statistically significant improvement in the primary endpoint, the six-minute walk test, compared to placebo. A subsequent open-label extension did show some patient-reported improvements in fatigue and function, but these were not robust enough to change the regulatory picture.

Her BTHS reference is accurate in a specific way. A smaller study by Thompson et al. (2021, Science Translational Medicine) did find that elamipretide improved cardiac and skeletal muscle function in BTHS patients, a rare X-linked condition caused by tafazzin gene mutations. The mechanism makes sense: SS-31 binds cardiolipin on the inner mitochondrial membrane and may stabilize mitochondrial architecture. But BTHS is a very narrow indication, not a proxy for general fatigue or aging.

What did they get wrong (or right)?

She got the broad strokes right, and that deserves credit. The framing that "just because it's popular doesn't mean you need it" is exactly the kind of skepticism that is missing from most peptide content. However, there are a few places where her characterization oversimplifies.

First, she implies that the 2018-2022 early studies were uniformly positive before things went wrong. That is a bit clean. The preclinical data in rodent models was strong, but the translation problem with mitochondria-targeted compounds is well-documented and was anticipated by researchers before Phase II even started.

Second, describing BTHS as just a "chronic disease" undersells how rare and specific it is. BTHS affects roughly 1 in 300,000 to 400,000 live births. Using it as a benchmark for who might benefit from SS-31 could inadvertently give false hope to people with more common fatigue conditions like long COVID or ME/CFS, where there is currently no clinical trial evidence supporting SS-31 use.

Third, she does not address why SS-31 is being used off-label through compounding pharmacies right now, or what the regulatory status of elamipretide actually is. That context matters for viewers considering whether to ask a provider about it.

What should you actually know?

SS-31, or elamipretide, is a synthetic tetrapeptide that targets cardiolipin on the inner mitochondrial membrane. Its proposed mechanism is real and backed by rigorous biochemistry. The problem is not the science of the molecule. The problem is that mitochondrial dysfunction in healthy or mildly symptomatic people does not respond to it the way it might in someone with a confirmed mitochondrial disease.

Elamipretide does not have FDA approval as of mid-2025. Stealth BioTherapeutics, the company that ran the major trials, filed for bankruptcy in 2022 after TAZPOWER results did not support approval. Compounded versions circulate in the off-label peptide market, but compounded elamipretide is not equivalent to the investigational drug studied in trials, and no Phase III data exists to establish safety or efficacy in general populations.

• If you have a confirmed mitochondrial disease, this is a conversation worth having with a specialist.
• If you are a generally healthy person chasing energy optimization, the current evidence does not support that use case.
• Animal and in vitro data remain active areas of research, particularly in aging models, but that is not a reason to self-administer an unapproved compound.